



## Evaluation of New Molecules in Severe Infectious Diseases

Guest Editors:

**Prof. Dr. Oriana Simonetti**

Dermatological Clinic-  
Department of Clinical and  
Molecular Sciences, Polytechnic  
University of the Marche Region,  
Ancona, Italy

**Prof. Dr. Elżbieta Kamysz**

Laboratory of Chemistry of  
Biological Macromolecules,  
Department of Molecular  
Biotechnology, Faculty of  
Chemistry, University of Gdansk,  
Gdańsk, Poland

Deadline for manuscript  
submissions:

**closed (31 December 2021)**

### Message from the Guest Editors

Dear Colleagues,

Hospital- and community-acquired Gram-positive and Gram-negative infections pose a substantial burden in terms of morbidity, mortality, and healthcare costs. The emergence of bacterial resistance to conventional antibiotics has become commonplace and heightened concern about the need for new drugs endowed with broader activity, which are useful in cases of infections unresponsive to common antimicrobial agents. Moreover, the introduction of new traditional antibiotics to counter these pathogens has frequently been closely followed by the emergence of resistant strains. For this reason, recent interest in the search for alternative therapeutics is growing, and it is becoming critical to identify effective agents to treat multidrug-resistant infections with novel mechanisms of activity.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*General Pharmacology, Toxicology and Pharmaceutics*)

## Contact Us

---

*Antibiotics* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
www.mdpi.com

mdpi.com/journal/antibiotics  
antibiotics@mdpi.com  
X@antibioticsmdpi